Journal ArticleDOI
Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study
TLDR
It is suggested that salmon calcitonin is effective in the treatment of osteoporosis and show that it acts on cortical and trabecular bone.Abstract:
Seventy-two postmenopausal osteoporotic women having more than one nontraumatic vertebral crush fracture were studied. Thirty-six of them, aged 68.8±1.2 years (18±4 YSM-years since menopause), were treated with 100 IU/day of salmon calcitonin i.m. plus 500 mg of elemental calcium for 10 days each month. The remaining 36 patients, aged 69.6±1.4 years (19±3 YSM), were given only 500 mg of elemental calcium for 10 days each month. All patients underwent clinical and analytical evaluation every 3 months. Radiological evaluation, assessment of vertebral deformities, and metacarpal radiogrammetry were done every 6 months. Densitometric measurements of total and regional bone mass were made every 12 months. At 24 months, the calcitonin group showed a 60% reduction in the number of new fractures and the group receiving only calcium had a 45% increase (P<0.001). The incidence of vertebral fractures was 0.07 per patient-year in the group treated with calcitonin and 0.45 per patient-year in the group treated with calcium (P<0.001). At 2 years, the calcitonin group showed a 12% increase in cortical bone mass on metacarpal radiogrammetry, a 16% increase in the axial skeleton on trunk densitometry, a 3.5% increase in total body bone mineral content, a 30.7% increase in pelvic bone mineral content, and a 6.2% increase in arm bone mineral content (all P<0.001). In the group treated with calcium alone there was a loss of bone mass in every region. These findings suggest that salmon calcitonin is effective in the treatment of osteoporosis and show that it acts on cortical and trabecular bone.read more
Citations
More filters
Journal ArticleDOI
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
Alexandra Papaioannou,Suzanne N Morin,Angela M. Cheung,Stephanie A. Atkinson,Jacques P. Brown,Sidney Feldman,David A. Hanley,Anthony B. Hodsman,Sophie A. Jamal,Stephanie M. Kaiser,Brent Kvern,Kerry Siminoski,William D. Leslie +12 more
TL;DR: There has been a paradigm shift in the prevention and treatment of osteoporosis and fractures, and the focus now is on preventing fragility fractures and their negative effects.
Journal ArticleDOI
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study
Charles H. Chesnut,Stuart L. Silverman,Kim Andriano,Harry K. Genant,Alberto Gimona,Steven T. Harris,Douglas P. Kiel,Meryl S. LeBoff,Michael Maricic,Paul D. Miller,Caje Moniz,Munro Peacock,P J Richardson,Nelson B. Watts,David J. Baylink +14 more
TL;DR: A 5-year, double-blind, randomized, placebo-controlled study was conducted to determine whether salmon calcitonin nasal spray reduced the risk of new vertebral fractures in postmenopausal women with osteoporosis.
Journal ArticleDOI
Treatment of postmenopausal osteoporosis.
TL;DR: The purpose of this review is to consider the evidence that treatments for postmenopausal osteoporosis are effective and safe.
Journal ArticleDOI
Bone mineral density thresholds for pharmacologic intervention to prevent fractures
Ethel S. Siris,Ya-Ting Chen,Thomas A. Abbott,Elizabeth Barrett-Connor,Paul D. Miller,Lois E. Wehen,Marc L. Berger +6 more
TL;DR: A strategy to reduce overall fracture incidence will likely require lifestyle changes and a targeted effort to identify and develop treatment protocols for women with less severe low bone mass who are nonetheless at increased risk for future fractures.
Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis
Catherine H. MacLean,Alicia Alexander,Jason Carter,Susan Chen,Sheetal B Desai,Jennifer M. Grossman,Margaret Maglione,Maureen McMahon,Melissa McNamara,Walter Mojica,Sydne J Newberry,Veena K. Ranganath,Marika J. Suttorp,Martha Timmer,Carlo Tringale,Di Valentine,Annie Zhou +16 more
TL;DR: In this article, the authors compared the benefits in fracture reduction and the harms from adverse events (AE) among and within the various classes of treatment for low bone density for vertebral, non-vertebral, hip, and radial fractures.
References
More filters
Journal ArticleDOI
Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.
B. Lawrence Riggs,Stephen F. Hodgson,W. Michael O'Fallon,Edmund Y. S. Chao,Heinz W. Wahner,Joan M. Muhs,Sandra L. Cedel,L. Joseph Melon +7 more
TL;DR: It is concluded that fluoride therapy increases cancellous but decreases cortical bone mineral density and increases skeletal fragility, and the fluoride-calcium regimen was not effective treatment for postmenopausal osteoporosis.
Journal ArticleDOI
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Nelson B. Watts,S. T. Harris,Harry K. Genant,Richard D. Wasnich,Paul D. Miller,Rebecca D. Jackson,A.A. Licata,Philip D. Ross,G C Woodson rd,M. J. Yanover +9 more
TL;DR: A prospective, two-year, double-blind, placebo-controlled, multicenter study in 429 women who had one to four vertebral compression fractures plus radiographic evidence of osteopenia to determine the effects of etidronate in the treatment of postmenopausal osteoporosis.
Journal ArticleDOI
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
TL;DR: Etidronate therapy for postmenopausal osteoporosis results in significant increases in vertebral bone mineral content and, after approximately one year of treatment, a significant decrease in the rate of new vertebral fractures.
Journal ArticleDOI
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Edward G. Lufkin,Heinz W. Wahner,William M. O'Fallon,Stephen F. Hodgson,Mark A. Kotowicz,Ann W. Lane,Howard L. Judd,Robert H. Caplan,B. Lawrence Riggs +8 more
TL;DR: Transdermal estradiol treatment is effective in postmenopausal women with established osteoporosis and vertebral fractures and Histomorphometric evaluation of iliac biopsy samples confirmed the effect of estrogen on bone formation rate per bone volume.
Journal ArticleDOI
Treatment of postmenopausal osteoporosis with calcitriol or calcium
TL;DR: Women who received calcitriol had a significant reduction in the rate of new vertebral fractures during the second and third years of treatment, as compared with the women who received calcium.